***Disease Modification in Individuals with Moderate-to-Severe Rheumatoid Arthritis: Optimizing Treatment Through the Finely Tuned Selectivity for JAKs***

|  |  |
| --- | --- |
| Resource | Address |
| Burmester G, Cohen S, Winthrop K, et al. Long-term safety profile of upadacitinib in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Presented at: ACR Convergence; November 9, 2021; Abstract 1691. | <https://acrabstracts.org/abstract/long-term-safety-profile-of-upadacitinib-in-patients-with-rheumatoid-arthritis-psoriatic-arthritis-or-ankylosing-spondylitis/> |
| Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. *Lancet*. 2013;381:451-460. | <https://pubmed.ncbi.nlm.nih.gov/23294500/> |
| Desai RJ, Pawar A, Weinblatt ME, Kim SC. Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: An observational cohort study. *Arthritis Rheumatol*. 2019;71:892-900. | <https://pubmed.ncbi.nlm.nih.gov/30552833/> |
| Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): A phase 3b/4, double-blind, head-to-head, randomised controlled trial. *Lancet.* 2017;390:457-468. | <https://pubmed.ncbi.nlm.nih.gov/28629665/> |
| Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 2021;73:924-939. | <https://pubmed.ncbi.nlm.nih.gov/34101387/> |
| Fragoulis GE, Brock J, Basu N, McInnes IB, Siebert. The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. *J Allergy Clin Immunol*. 2021;148:941-952. | <https://pubmed.ncbi.nlm.nih.gov/34450118/> |
| Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): A double-blind, randomised controlled phase 3 trial. *Lancet*. 2018;391:2513-2524. | <https://pubmed.ncbi.nlm.nih.gov/29908670/> |
| Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. *N Engl J Med.* 2016;374:1243-1252. | <https://pubmed.ncbi.nlm.nih.gov/27028914/> |
| Köhler BM, Günther J, Kaudewitz D, Lorenz HM. Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. *J Clin Med*. 2019;8:938. | <https://pubmed.ncbi.nlm.nih.gov/31261785/> |
| Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. *N Engl J Med.* 2020;383:1511-1521. | <https://pubmed.ncbi.nlm.nih.gov/33053283/> |
| Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. *Ann Rheum Dis*. 2010;69:631-637. | <https://pubmed.ncbi.nlm.nih.gov/20215140/> |
| Ytterberg SR, Bhatt DL, Mikuls T, et al. Safety and efficacy of tofacitinib vs TNF inhibitors in RA patients aged 50 years or older with one or more cardiovascular risks: Results from a phase 3b/4 randomized safety trial. Presented at: ACR Convergence; November 7, 2021; Abstract 831. | <https://acrabstracts.org/abstract/safety-and-efficacy-of-tofacitinib-vs-tnf-inhibitors-in-ra-patients-aged-50-years-or-older-with-one-or-more-cardiovascular-risks-results-from-a-phase-3b-4-randomized-safety-trial/> |